［1］ WONG V K， CHIU P， CHUNG S S， et al. Pseudolaric acid B， a novel microtubule-destabilizing agent that circumvents multidrug resistance phenotype and exhibits antitumor activity in vivo[J]. Clin Cancer Res， 2005， 11(16)： 6002-6011.
［2］ GONG X F， WANG M W， WU Z， et al. Pseudolaric acid B induces apoptosis via activation of c-Jun N-terminal kinase and caspase-3 in HeLa cells[J]. Exp Mol Med， 2004， 36(6)： 551-556.
［3］ GONG X F， WANG M W， TASHIRO S， et al. Pseudolaric acid B induces apoptosis through p53 and Bax/Bcl-2 pathways in human melanoma A375-S2 cells[J]. Arch Pharm Res（亚洲天然产物研究）， 2005， 28(1)：68-72.
［4］ LIU B， CHEN H， LEI Z Y， et al. Studies on anti-tumour activities of pseudolaric acid-B (PLAB) and its mechanism of action[J]. J Asian Nat Prod Res（亚洲天然药物研究）， 2006，8(3)： 241-252.
［5］ TONG Y G， ZHANG X W， GENG M Y， et al. Pseudolarix acid B， a new tubulin-binding agent， inhibits angiogenesis by interacting with a novel binding site on tubulin [J]. Mol Pharmacol， 2006， 69(4)：1226-1233.
［6］ XU Y H， WANG X Q， JU X H， et al. Molecular mechanisms of pseudolaric acid B induced apoptosis in SGC7901 cells[J]. Chin Pharm Bull(中国药理学通报)， 2008，24 (5)： 601-606.
［7］ GONG X F， WANG M W， TASHIRO S， et al. Pseudolaric acid B induces human melanoma A375-S2 cell apoptosis in vitro[J]. China J Chin Mat Med(中国中药杂志)， 2005，30（1）：55-57.
［8］ KO J K S， LEUNG W C， HO W K， et al. Herbal diterpenoids induce growth arrest and apoptosis in colon cancer cells with increased expression of the nonsteroidal anti-inflammatory drug-activated gene[J]. Eur J Pharmacol， 2007， 559(1)： 1-13.
［9］ MA G， CHONG L， LI X C， et al. Selective inhibition of human leukemia cell growth and induction of cell cycle arrest and apoptosis by pseudolaric acid B[J]. J Cancer Res Clin Oncol， 2010， 136（9）：1333-1340.
［10］ SQUIRES M S， HUDSON E A， HOWELLS L， et al. Relevance of mitogen activated protein kinase (MAPK) and phosphotidylinositol-3-kinase /protein kinase B ( PI3K/PKB) pathways to induction of apoptosis by curcumin in breast cells[J]. Biochem Pharmacol， 2003， 65 (3)： 361-376.
［11］ DENT P， YACOUB A， FISHER P B， et al. MAPK pathways in radiation responses[J]. Oncogene， 2003， 22 (37)： 5885-5896.
［12］ TORII S， NAKAYAMA K， YAMAMOTO T， et al.Regulatory mechanisms and function of ERK MAP kinases[J]. J Biochem (Tokyo)， 2004，136 (5)： 557-561.
［13］ ZARUBIN T， HAN J H. Activation and signaling of the p38 MAP kinase pathway[J]. Cell Res， 2005， 15 (1)： 11-18.
［14］ LIU J， LIN A. Role of JNK activation in apoptosis： a double-edged sword[J]. Cell Res， 2005， 15 (1)： 36-42.
［15］ GONG X， WANG M， TASHIRO S， et al. Involvement of JNK-initiated p53 accumulation and phosphorylation of p53 in pseudolaric acid B induced cell death[J]. Exp Mol Med， 2006， 38： 428-434.
［16］ YU J H， WANG H J， LI X R， et al. Protein tyrosine kinase， JNK， and ERK involvement in pseudolaric acid B-induced apoptosis of human breast cancer MCF-7 cells[J]. Acta Pharmacol Sin（中国药理学报）， 2008，29 (9)： 1069-1076.
［17］ REN Z， FANG L， SHEN H W， et al. Pseudolaric acid B induces apoptosis via PI-3K / Akt pathway in cervical carcinoma HeLa cells[J].J Sun Yat-Sen Univ（Med Ed）(中山大学学报：医学科学版）， 2008，29（6）：659-663.
［18］ MURATA H， TSUJI S， TSUJII M， et al. Promoter hypermethylation silences cyclooxygenase-2 ( COX-2) and regulates growth of human hepatocellular carcinoma cells[J]. Lab Invest， 2004， 84 (8)：1050-1059.
［19］ JU X H， XU Y H， LI Y. Effects of pseudolaric acid B on the apoptosis， mitochondrial membrane potential and cyclooxygenase-2 expression in hepatocellular carcinoma cell line BEL-7402[J]. World J Gastroenterol (世界华人消化杂志)，2008，16(11)： 1151-1156.
［20］ BAEK S J， KIM K S， NIXON J B， et al. Cyclooxygenase inhibitors regulate the expression of a TGF-beta superfamily member that has proapoptotic and antitumorigenic activities[J]. Mol Pharmacol， 2001， 59 (4)：901-908.
［21］ TAN W F， ZHANG X W， LI M H， et al. Pseudolarix acid B inhibits angiogenesis by antagonizing the vascular endothelial growth factor-mediated anti-apoptotic effect[J]. Eur J Pharmacol， 2004， 499(3)：219- 228.
［22］ LI MH，MIAO Z H， TAN W F， et al. Pseudolaric acid B inhibits angiogenesis and reduces hypoxia-inducible factor 1 alpha by promoting proteasome-mediated degradation[J]. Clin Cancer Res， 2004， 10(1)： 8266-8274.
［23］ SEMELA D， DUFOUR J F. Angiogenesis and hepatocellular carcinoma[J]. J Hepatol， 2004， 41(5)： 864-880.
［24］ SHIBATA A， NAKAGAWA K， SOOKWONG P， et al. Tocotrienol inhibits secretion of angiogenic factors from human colorectal adenocarcinoma cells by suppressing hypoxia-inducible factor-1[alpha]1-3[J]. The J Nutrition， 2008， 138(11)：2136-2143.
［25］ YU J H， CUI Q， JIANG Y Y， et al. Pseudolaric acid B induces apoptosis， senescence， and mitotic arrest in human breast cancer MCF-7[J]. Acta Pharmacol Sin（中国药理学报）， 2007， 28 (12)： 1975-1983.
［26］ MENG A G， JIANG L L. Induction of G2/M arrest by pseudolaric acid B is mediated by activation of the ATM signaling pathway[J].Acta Pharmacol Sin（中国药理学报）， 2009， 30(4)：442-450.
［27］ YU J H， TASHIRO S， ONODERA S， et al. Pseudolaric acid B induced apoptosis and mitotic arrest circumventing Fas receptor pathway in MCF-7 cells[J]. Chin Pharmacol Bull(中国药理学通报)， 2008，24 (11)： 1509-1513.
［28］ JARDAT M S， NOONAN D J， WU B， et al. Pseudolaric acid analogs as a new class of peroxisome proliferator-activated receptor agonists [J].Planta Med， 2002， 68 (8)： 667-671.
［29］ HU Y， LI K S， MAO D W. Effect of pseudolaric acid B on telomerse activity and related genes of human ovarian cancer cells[J]. J Prev Med Chin PLA(解放军预防医学杂志)， 2007， 25 (1)：31-33.